Biosion Secures B+ Financing to Advance Innovative Antibody Discovery Platforms and Global Commercialization Strategy

VCBeat has learned that Biosion, a global innovative biotechnology company in the clinical stage, has announcedFollowing the completion of its over RMB 100 million Series B financing in December 2022, the company has recently secured an additional round of financing amounting to tens of millions of yuan., to consolidate and strengthen the development and advancement of Biosion’s global innovation pipeline, while also providing financial support for the Company’s robust innovative antibody discovery platform.This additional round of financing involved Ruiying Asset, Hemeng Venture Capital, and its founding cornerstone investor, Mr. Wang Huachun.

Dr. Chen Mingjiu, Founder, Chairman, and CEO of Biosionstated, “We sincerely appreciate the recognition and strong support from both new and existing investors in Biosion. In the current capital winter, securing renewed investor interest and additional funding within a short period underscores the investment community’s endorsement of Biosion’s ‘In Global For Global’ development model. We will continue to build an international management team, further strengthen our self-sustaining capabilities, and comprehensively advance our global collaboration strategy, working hand in hand with partners worldwide to accelerate the expansion of Biosion’s innovative drug pipeline.”

Dr. Ye Xinliang, Director, Chief Strategy Officer, and Head of Business Development for China at BiosionThe company stated, “Leveraging Biosion’s three leading innovative antibody discovery platforms, we have developed a competitive portfolio of drug candidates. Our lead asset, BSI-045B, is currently undergoing global Phase II clinical trials for atopic dermatitis in the United States, while our partner, Chia Tai Tianqing Pharmaceutical Group, is vigorously advancing Phase II clinical trials for severe asthma in Greater China. Meanwhile, patient enrollment for Phase I or II clinical trials of four additional innovative drug collaboration projects is set to commence shortly in China and the United States, further underscoring Biosion’s technological advantages in the field of innovative antibody drug discovery. The completion of this financing round will consolidate the development progress of our drug pipeline and accelerate the realization of our corporate vision to develop breakthrough innovative biologics for patients worldwide.”

Hemeng Venture Capital’s Medical and Biological Fund focuses on investments in innovative medical care, pharmaceuticals, and frontier biotechnologies. It strategically targets niche sectors such as novel cell and immunotherapies, nucleic acid and gene-based drugs and vaccines, omics-based diagnostic methods and tools, as well as advanced medical devices and consumables. Adhering to an investment philosophy that equally emphasizes innovation, growth, and value, the fund has invested in projects including Pintai Optoelectronics, Rongzhi Biology, Aoruiji Medical, Kedou Medicine, Shangjian Biology, Suosi Medical, Zhongsheng Kangyuan, Huichuang Medical, and Wangshan Wangshui.

Ruiying Asset Management, established in October 2017, focuses on strategic investments in healthcare, high-end manufacturing, and new materials, with assets under management exceeding RMB 1 billion. The firm adheres to an investment philosophy centered on “identifying project value through market analysis and scientific research, enhancing capital liquidity to create value, and ultimately driving value appreciation through operational and managerial excellence.” Primarily engaged in strategic investments, Ruiying collaborates with R&D institutions and capital partners to facilitate strategic incubation and resource integration. Its portfolio includes numerous high-growth companies such as iVAC, MyBiologics, Newreat, Cayudi, Arthur Pharma, Hepu Pharmaceutical, and Jiudao Technology.

Biosion is a clinical-stage global innovative biotechnology company dedicated to developing innovative therapies by leveraging its proprietary antibody technology platform, with the aim of benefiting patients in the treatment of immune and oncological diseases. Founded in 2017, Biosion has built its internal proprietary H^³(High-throughput, High-content, High-efficiency) Antibody Discovery Platform, SynTracer^®High-Throughput Antibody Internalization Screening Platform, and Flexibody^® Leveraging its bispecific antibody technology platform and global collaborations, the company has established a pipeline of innovative drug candidates. Its internally developed product, BSI-045B (an anti-TSLP monoclonal antibody), is currently undergoing Phase II clinical trials in China and the United States for the treatment of severe asthma and atopic dermatitis. Additionally, patient recruitment for Phase I or II clinical trials of four other internally developed collaborative products is imminent in both China and the United States. Biosion maintains branches in China, the United States, and Australia.